Recce Pharmaceuticals Ltd is a biotechnology firm dedicated to the discovery, development, and commercialization of cutting-edge synthetic anti-infective treatments. The company's operations span major markets, including Australia, the United States, and the United Kingdom. Its primary drug candidate, RECCE 327, is engineered to combat severe blood infections and sepsis caused by E. coli and S. aureus bacteria, critically, even their antibiotic-resistant 'superbug' forms. In addition to RECCE 327, the company's pipeline includes RECCE 529, another synthetic anti-infective being developed for viral infections, and RECCE 435, a synthetic polymer anti-infective. Founded in 2007, the company originally operated as Recce Limited before officially rebranding to Recce Pharmaceuticals Ltd in November 2017. It maintains its headquarters in Sydney, Australia.
—
Recce Pharmaceuticals Ltd is a biotechnology firm dedicated to the discovery, development, and commercialization of cutting-edge synthetic anti-infective treatments. The company's operations span major markets, including Australia, the United States, and the United Kingdom. Its primary drug candidate, RECCE 327, is engineered to combat severe blood infections and sepsis caused by E. coli and S. aureus bacteria, critically, even their antibiotic-resistant 'superbug' forms. In addition to RECCE 327, the company's pipeline includes RECCE 529, another synthetic anti-infective being developed for viral infections, and RECCE 435, a synthetic polymer anti-infective. Founded in 2007, the company originally operated as Recce Limited before officially rebranding to Recce Pharmaceuticals Ltd in November 2017. It maintains its headquarters in Sydney, Australia.
—
Daily adjusted close
Recce Pharmaceuticals Ltd is a biotechnology firm dedicated to the discovery, development, and commercialization of cutting-edge synthetic anti-infective treatments. The company's operations span major markets, including Australia, the United States, and the United Kingdom. Its primary drug candidate, RECCE 327, is engineered to combat severe blood infections and sepsis caused by E. coli and S. aureus bacteria, critically, even their antibiotic-resistant 'superbug' forms. In addition to RECCE 327, the company's pipeline includes RECCE 529, another synthetic anti-infective being developed for viral infections, and RECCE 435, a synthetic polymer anti-infective. Founded in 2007, the company originally operated as Recce Limited before officially rebranding to Recce Pharmaceuticals Ltd in November 2017. It maintains its headquarters in Sydney, Australia.